Fibrates are a class of prescription medications used primarily to lower triglycerides, a type of fat in the blood. They can reduce triglyceride levels by 25 to 50% and raise HDL (good) cholesterol by 5 to 20%. The two most commonly prescribed fibrates are fenofibrate and gemfibrozil, though bezafibrate is also available in some countries.
How Fibrates Work
Fibrates activate a receptor inside cells called PPAR-alpha, which acts like a master switch for genes involved in fat metabolism. When this switch flips on, your body ramps up its ability to break down fatty acids and clear triglycerides from the bloodstream. At the same time, fibrates boost production of an enzyme that dismantles triglyceride-rich particles and reduce production of a protein that normally slows that process down.
The effects on HDL cholesterol come through a separate pathway. Fibrates increase the production of two key building blocks of HDL particles, which is why good cholesterol levels tend to rise alongside the drop in triglycerides.
Who Takes Fibrates
Fibrates are most often prescribed for people with high triglycerides, particularly when levels are high enough to raise the risk of pancreatitis (typically above 500 mg/dL). They’re also used for people with a lipid pattern that includes both elevated triglycerides and low HDL cholesterol, a combination common in type 2 diabetes and metabolic syndrome.
For most people with high LDL (bad) cholesterol alone, statins are the first choice. Fibrates fill a different role, targeting the triglyceride side of the equation. Some people take both, though that combination requires careful consideration because of interaction risks covered below.
Impact on Heart Disease Risk
A large meta-analysis published in The Lancet pooled data from 18 clinical trials with over 45,000 participants. Fibrate therapy reduced the risk of major cardiovascular events by 10% and coronary events specifically by 13%. However, fibrates showed no benefit for stroke prevention and did not reduce the risk of dying from heart disease or any other cause. This is an important distinction: fibrates improve lipid numbers and modestly lower the chance of a heart attack, but they haven’t been shown to help people live longer overall.
Fibrates vs. Omega-3 Supplements
Prescription omega-3 fatty acids are another option for high triglycerides, and the two are sometimes compared. In a head-to-head trial, fenofibrate lowered triglycerides by 29% while omega-3s reduced them by 21%. Both improved blood vessel function to a similar degree. But fenofibrate outperformed omega-3s on several other measures: it raised HDL cholesterol more, lowered non-HDL cholesterol, improved insulin sensitivity, and increased adiponectin, a hormone linked to better metabolic health. For people whose primary concern is triglycerides alone, omega-3s may be sufficient, but fenofibrate offers broader metabolic benefits.
Common Side Effects
Most people tolerate fibrates without major problems. In clinical trials of fenofibrate, about 5% of patients stopped the medication due to side effects, compared to 3% on placebo. The most frequently reported issues include:
- Abnormal liver tests: 7.5% of patients, compared to 1.4% on placebo. This is the most notable side effect and the reason regular blood work is recommended.
- Abdominal pain: 4.6% of patients
- Back pain and headache: around 3% each
- Elevated muscle enzymes: 3% of patients, which can signal muscle irritation
- Nausea and constipation: roughly 2% each
Fibrates can also raise creatinine levels in blood tests, though it’s not entirely clear whether this reflects actual changes in kidney function or just an artifact of the medication. Dizziness, joint pain, and mild respiratory symptoms like nasal congestion are also reported.
The Statin Combination Risk
Combining a fibrate with a statin increases the risk of rhabdomyolysis, a rare but serious condition where muscle tissue breaks down and releases proteins that can damage the kidneys. The risk varies dramatically depending on which fibrate is used. Gemfibrozil combined with statins carries a substantially higher risk than fenofibrate does. One particularly dangerous combination, cerivastatin (now withdrawn from the market) with gemfibrozil, had a rhabdomyolysis rate roughly 50 to 60 times higher than other statin-fibrate pairings.
For this reason, when a fibrate needs to be combined with a statin, fenofibrate is the strongly preferred choice. Gemfibrozil is generally considered unsafe to use alongside statins because it interferes with how the body processes them, leading to dangerously high statin levels in the blood.
Monitoring While on Fibrates
If you’re prescribed a fibrate, expect blood work before starting and again 6 to 8 weeks later to check your lipid levels and liver enzymes. Regular liver function tests are recommended throughout treatment. Muscle enzyme levels don’t need routine monitoring unless you develop muscle pain or weakness, at which point your provider will check them. For people with risk factors like diabetes or already elevated creatinine, yearly kidney function checks are also recommended.
Once your lipid levels stabilize and you’re in a good range, annual blood work is typically sufficient to stay on track.